Bimatoprost

Bimatoprost

Error creating thumbnail: File missing
Clinical data
Routes of administration	Topical (eye drops)
ATC code	S01EE03 (WHO)
Identifiers
IUPAC name 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide
CAS Number	155206-00-1
PubChem CID	5311027
DrugBank	APRD00826
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C25H37NO4
Molar mass	415.566 g/mol

WikiDoc Resources for Bimatoprost
Articles
Most recent articles on Bimatoprost Most cited articles on Bimatoprost Review articles on Bimatoprost Articles on Bimatoprost in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bimatoprost Images of Bimatoprost Photos of Bimatoprost Podcasts & MP3s on Bimatoprost Videos on Bimatoprost
Evidence Based Medicine
Cochrane Collaboration on Bimatoprost Bandolier on Bimatoprost TRIP on Bimatoprost
Clinical Trials
Ongoing Trials on Bimatoprost at Clinical Trials.gov Trial results on Bimatoprost Clinical Trials on Bimatoprost at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bimatoprost NICE Guidance on Bimatoprost NHS PRODIGY Guidance FDA on Bimatoprost CDC on Bimatoprost
Books
Books on Bimatoprost
News
Bimatoprost in the news Be alerted to news on Bimatoprost News trends on Bimatoprost
Commentary
Blogs on Bimatoprost
Definitions
Definitions of Bimatoprost
Patient Resources / Community
Patient resources on Bimatoprost Discussion groups on Bimatoprost Patient Handouts on Bimatoprost Directions to Hospitals Treating Bimatoprost Risk calculators and risk factors for Bimatoprost
Healthcare Provider Resources
Symptoms of Bimatoprost Causes & Risk Factors for Bimatoprost Diagnostic studies for Bimatoprost Treatment of Bimatoprost
Continuing Medical Education (CME)
CME Programs on Bimatoprost
International
Bimatoprost en Espanol Bimatoprost en Francais
Business
Bimatoprost in the Marketplace Patents on Bimatoprost
Experimental / Informatics
List of terms related to Bimatoprost

Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It is known by the brand name of Lumigan in USA, manufactured by Allergan Inc. Bimatoprost ophthalmic solution 0.03% is a synthetic prostamide analog with ocular hypotensive activity. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[1E,3S) -3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]- 5-N-ethylheptenamide, and its molecular weight is 415.58. Its molecular formula is C₂₅H₃₇NO₄.

Side effects

Possible side effects of this medication are:

• May cause blurred vision;
• May cause eyelid redness;
• May permanently darken eyelashes;
• May cause eye discomfort;
• May eventually cause permanent darkening of the iris to brown (heterochromia).
• May cause a temporary burning sensation during use.
• May cause thickening of the eyelashes.

References

• Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma". J Ocul Pharmacol Ther. 22 (3): 188–93. PMID 16808680.CS1 maint: Multiple names: authors list (link)
• Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klin Monatsbl Augenheilkd. 223 (6): 534–7. PMID 16804825.CS1 maint: Multiple names: authors list (link)
• Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy". Optometry. 77 (4): 177–9. PMID 16567279.

External links

Template:WS